Key result
Testosterone supplementation was not associated with an increased risk of cardiovascular events across 75 randomized trials including 5,464 patients.
Meta-Analysis (n=5,464)
INTRODUCTION: Recent reports have significantly halted the enthusiasm regarding androgen-boosting; suggesting that testosterone supplementation (TS) increases cardiovascular (CV) events. AREAS COVERED: In order to overcome some of the limitations of the current evidence, the authors performed an updated systematic review and meta-analysis of all placebo-controlled randomized clinical trials (RCTs) on the effect of TS on CV-related problems. Out of 2747 retrieved articles, 75 were analyzed, including 3016 and 2448 patients in TS and placebo groups, respectively, and a mean duration of 34 weeks. Our analyses, performed on the largest number of studies collected so far, indicate that TS is not related to any increase in CV risk, even when composite or single adverse events were considered. In RCTs performed in subjects with metabolic derangements a protective effect of TS on CV risk was observed. EXPERT OPINION: The present systematic review and meta-analysis does not support a causal role between TS and adverse CV events. Our results are in agreement with a large body of literature from the last 20 years supporting TS of hypogonadal men as a valuable strategy in improving a patient's metabolic profile, reducing body fat and increasing lean muscle mass, which would ultimately reduce the risk of heart disease.
No takes yet. Share an insight, caveat, or question.
Corona et al. (2014) conducted a meta-analysis in Hypogonadism/Cardiovascular risk (n=5,464). Testosterone supplementation vs. Placebo was evaluated on Cardiovascular adverse events. Testosterone supplementation was not associated with an increased risk of cardiovascular events across 75 randomized trials including 5,464 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: